On Tuesday, Arcus Biosciences Inc (NYSE: RCUS) opened lower -1.50% from the last session, before settling in for the closing price of $16.66. Price fluctuations for RCUS have ranged from $12.95 to $20.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 164.80% over the last five years. Company’s average yearly earnings per share was noted 20.96% at the time writing. With a float of $48.07 million, this company’s outstanding shares have now reached $75.50 million.
The firm has a total of 577 workers. Let’s measure their productivity. In terms of profitability, gross margin is 94.74%, operating margin of -118.62%, and the pretax margin is -99.6%.
Arcus Biosciences Inc (RCUS) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Arcus Biosciences Inc is 47.43%, while institutional ownership is 52.82%. The most recent insider transaction that took place on Aug 13 ’24, was worth 20,314. In this transaction Chief Accounting Officer of this company sold 1,357 shares at a rate of $14.97, taking the stock ownership to the 19,070 shares. Before that another transaction happened on Mar 27 ’24, when Company’s Chief Operating Officer sold 11,551 for $17.55, making the entire transaction worth $202,720. This insider now owns 215,253 shares in total.
Arcus Biosciences Inc (RCUS) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.94 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -1.13) by 0.19. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.96% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.80% during the next five years compared to -23.70% drop over the previous five years of trading.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
Check out the current performance indicators for Arcus Biosciences Inc (RCUS). In the past quarter, the stock posted a quick ratio of 5.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.10, a number that is poised to hit -1.06 in the next quarter and is forecasted to reach -4.11 in one year’s time.
Technical Analysis of Arcus Biosciences Inc (RCUS)
Analysing the last 5-days average volume posted by the [Arcus Biosciences Inc, RCUS], we can find that recorded value of 1.18 million was better than the volume posted last year of 0.73 million. As of the previous 9 days, the stock’s Stochastic %D was 14.34%. Additionally, its Average True Range was 1.05.
During the past 100 days, Arcus Biosciences Inc’s (RCUS) raw stochastic average was set at 52.93%, which indicates a significant increase from 16.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.21% in the past 14 days, which was higher than the 59.19% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.88, while its 200-day Moving Average is $16.37. Now, the first resistance to watch is $17.03. This is followed by the second major resistance level at $17.66. The third major resistance level sits at $18.08. If the price goes on to break the first support level at $15.98, it is likely to go to the next support level at $15.56. Should the price break the second support level, the third support level stands at $14.93.
Arcus Biosciences Inc (NYSE: RCUS) Key Stats
There are currently 91,428K shares outstanding in the company with a market cap of 1.50 billion. Presently, the company’s annual sales total 117,000 K according to its annual income of -307,000 K. Last quarter, the company’s sales amounted to 39,000 K and its income totaled -93,000 K.
